Doxepin Indications and Dosing
Doxepin is FDA-approved for depression and anxiety, with doses of 75-300 mg/day for these psychiatric indications, while low-dose doxepin (3-6 mg) is specifically approved for insomnia and should be reserved for patients unable or unwilling to receive cognitive behavioral therapy for insomnia (CBT-I). 1, 2
Primary Indications
1. Depression and Anxiety (Traditional Dosing)
The FDA-approved indication uses higher doses 2:
- Starting dose: 75 mg/day for mild-to-moderate illness
- Optimal range: 75-150 mg/day for most patients
- Severe illness: May require up to 300 mg/day (doses above 300 mg/day rarely provide additional benefit)
- Mild symptoms/organic disease: 25-50 mg/day may suffice
- Administration: Can be given as divided doses or once-daily at bedtime (maximum 150 mg for once-daily dosing)
- Onset: Anti-anxiety effects appear before antidepressant effects; optimal antidepressant response may take 2-3 weeks 2
2. Chronic Insomnia (Low-Dose Formulation)
Low-dose doxepin (3 or 6 mg) should only be offered as a short course when CBT-I is unavailable or refused, as behavioral interventions demonstrate superior long-term outcomes. 1
The 2019 VA/DoD guidelines emphasize this hierarchical approach because CBT-I shows equivalent short-term results (2-4 weeks) but superior long-term outcomes compared to pharmacotherapy, with fewer adverse effects 1.
Dosing for insomnia:
- Effective doses: 3 mg or 6 mg at bedtime
- Duration: Short courses only (evidence beyond brief treatment periods is lacking)
- Efficacy: Improves sleep maintenance, total sleep time, and sleep quality; the 6 mg dose also reduces sleep onset latency 1, 3
- Age considerations: Both 3 mg and 6 mg doses effective in older adults; 6 mg dose showed benefit in younger adults 1
3. Pruritus (Off-Label)
Low-dose doxepin (10 mg three times daily) serves as an alternative for pruritus associated with allergic cutaneous reactions when conventional antihistamines fail, likely due to its potent H1 and H2 blocking properties 4.
Critical Dosing Considerations
Elderly Patients
Start at the low end of the dosing range due to increased risk of confusion, oversedation, and decreased renal/hepatic function 2. The once-daily regimen requires careful adjustment based on patient condition.
Pediatric Patients
Not recommended for children under 12 years of age 2. A case report documented severe chronic toxicity in a 10-year-old prescribed 4.41 mg/kg (300 mg) nightly, resulting in seizures and confusion that resolved upon discontinuation 5.
Pharmacogenomic Variability
Significant interindividual variation exists in doxepin plasma levels at identical doses due to CYP2D6 and CYP2C19 polymorphisms 6. Blood level monitoring can optimize dosing in patients unresponsive to typical doses, preventing premature labeling as treatment failures 6.
Drug Interactions
CYP2D6 inhibitors (e.g., clobazam) and CYP2C19 inhibitors (e.g., topiramate) can precipitate toxicity even at therapeutic doses 5.
Safety Profile
Black Box Warning: All antidepressants carry FDA warnings for increased suicidal thinking and behavior in children, adolescents, and young adults (ages 18-24) with major depressive disorder and other psychiatric disorders 2. Close monitoring is essential during initial treatment and dose adjustments.
Common adverse effects at traditional doses include anticholinergic effects (dry mouth, blurred vision, constipation, urinary retention), drowsiness, and cardiovascular effects (hypotension, tachycardia) 2.
Low-dose doxepin (3-6 mg) demonstrates a safety profile comparable to placebo with no significant next-day residual sedation, no anticholinergic effects, and preserved sleep architecture 3. However, adverse event incidence may increase with longer treatment duration 1.
Key Clinical Pitfalls
- Avoid abrupt discontinuation after prolonged use to prevent withdrawal symptoms 2
- Screen for bipolar disorder before initiating treatment, as antidepressant monotherapy may precipitate manic episodes 2
- Monitor for angle-closure glaucoma in patients with anatomically narrow angles 2
- Do not exceed 150 mg when using once-daily dosing for depression 2
- Recognize chronic toxicity presenting as confusion, ataxia, or seizures in patients on maintenance therapy, particularly with drug interactions or genetic polymorphisms 5